Daily Bulletin

Men's Weekly

.

  • Written by Pitch Engine
image

Global CINV Drugs Market 2015-2019 is a new research report added by Sandlerresearch.org under the Pharmaceutical category.

CINV is one of the most dreaded adverse effects of chemotherapy. It often leads to the postponement or refusal of potentially curative chemotherapy treatment for cancer. This nausea and vomiting, associated with chemotherapy regimen, affects the quality of life of an individual.

The neurotransmitters in CINV are dopamine, 5-HT3, substance P, and endocannabinoids. CINV can be caused by the stimulation of vomiting center by the abdominal vagal afferents or by the direct stimulation of CTZ in the area postrema. The risk of development of CINV changes with the use of different types of chemotherapy regimens such as high, moderate, low, and minimal risk.

Based on the type of CINV, different treatment regimens are prescribed. The classes of drugs used in the treatment of CINV are 5-HT3 receptor antagonists, NK1 receptor antagonists, corticosteroids, dopamine antagonists, benzodiazepines, and cannabinoids. Most of the drugs used in the treatment are helpful in the prevention of vomiting but show less effect in treating nausea.

The analysts forecast global chemotherapy induced nausea and vomiting drugs market to grow at a CAGR of 4.9% over the period 2014-2019.

Covered in this Report

The report covers present scenario and the growth prospects of the global CINV drugs market for the period 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various branded therapies and generics along with the drugs used as off-label for the treatment of CINV.

The report, Global CINV Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, APAC, and EMEA; it also covers the landscape of the global CINV drugs market and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

Purchase a copy of the report at http://www.sandlerresearch.org/purchase?rname=41611 .

Key regions

Key vendors

  • GlaxoSmithKline
  • Helsinn
  • Heron Therapeutics
  • Merck & Co
  • Tesaro

Other prominent vendors

  • Acacia Pharma
  • Aphios
  • Barr Laboratories
  • Baxter Healthcare
  • Eisai
  • Especificos Stendhal
  • F.Hoffmann La Roche
  • Mundipharma
  • Mylan Pharmaceuticals
  • OPKO Health
  • Orchid Healthcare
  • Otsuka Pharmaceutical
  • ProStrakan
  • Sandoz (Novartis)
  • Solvay Pharmaceuticals
  • Specialised Therapeutics Australia
  • Sun Pharma
  • Taiho Pharmaceutical
  • Teva Pharmaceuticals

Market driver

  • Increase in incidence and prevalence of cancer

Market challenge

  • Complex physiology of CINV

Market trend

  • Increased use of combination therapies

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?
For more Information on the report, inquire at http://www.sandlerresearch.org/inquire-before-buying?rname=41611 .

About US:

Sandlerresearch.org is an online market research store for research reports on multiple industries. These reports provide market analysis, trends and opportunities and forecast about industries that helps to make a right decision for the business.

Authors: Pitch Engine

Read more http://www.pitchengine.com/pitches/35d3af41-3f5e-4509-94c4-b2ffa0f75ea4

Business News

Hydrogen Pipe Infrastructure: A Guide to Future Networks

As Australia moves towards a cleaner energy future, hydrogen is emerging as a key player. But how do we get this promising energy source from production facilities to where it's needed? The answer l...

Daily Bulletin - avatar Daily Bulletin

Wang Chuanfu Attends BYD Harmony’s 100th Overseas Store Opening

Dignitaries inaugurate the new store On July 12, 2025, Melbourne, the vibrant pearl of the southern hemisphere, Chairman and President of BYD Co., Ltd. Mr. Wang Chuanfu inaugurated and awarded the ...

Daily Bulletin - avatar Daily Bulletin

Strategic Global Expansion Moves to Overcome the Growth Challenges

Photo by Gabrielle Henderson on Unsplash Australia's startup ecosystem is having a moment in the sun. Out of 1,257 unicorns globally, eight hail from Australia. Yet, trade and economic policy uncerta...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals